ADMA Biologics (ADMA) Issues Statement on Tariffs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall Street ends down as expectations of Hormuz deal fade
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Nvidia and Wall Street giants plan $500B AI funding deal, FT reports
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil climbs 5% as Iran, US both demand compensation and Hormuz hopes fade
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
ADMA Biologics Statement on Tariffs
April 7, 2025 7:00 AM EDTReiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated U.S.-Based Supply Chain
RAMSEY, N.J. and BOCA RATON, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (ADMA or the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today provided a statement on the recent tariffs put in place and reiterated ADMAs strategic advantage through fully U.S.-based manufacturing operations, commercialization and end-market sales, and a vertically integrated... More
